{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:57:17Z","timestamp":1791482237804,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Familial Hypercholesterolemia (FH) is a common genetic disorder caused most often by mutations in the Low Density Lipoprotein Receptor gene (<jats:italic>LDLr<\/jats:italic>) leading to high blood cholesterol levels, and ultimately to development of premature coronary heart disease. Genetic analysis and subsequent cascade screening in relatives allow diagnosis of FH at early stage, especially relevant to diagnose children. So far, more than 2300 LDLr variants have been described but only a minority of them have been functionally analysed to evaluate their pathogenicity in FH. Thus, identifying pathogenic mutations in LDLr is a long-standing challenge in the field. In this study, we investigated <jats:italic>in vitro<\/jats:italic> the activity p.(Asp47Asn) and p.(Thr62Met) <jats:italic>LDLr<\/jats:italic> variants, both in the LR1 region. We used CHO-<jats:italic>ldlA7<\/jats:italic> transfected cells with plasmids carrying p.(Asp47Asn) or p.(Thr62Met) <jats:italic>LDLr<\/jats:italic> variants to analyse LDLr expression by FACS and immunoblotting, LDL binding and uptake was determined by FACS and analysis of mutation effects was assessed <jats:italic>in silico<\/jats:italic>. The <jats:italic>in vitro<\/jats:italic> activity assessment of p.(Asp47Asn) and p.(Thr62Met) <jats:italic>LDLr<\/jats:italic> variants shows a fully functional LDL binding and uptake activities. Therefore indicating that the three of them are non-pathogenic LDLr variants. These findings also emphasize the importance of <jats:italic>in vitro<\/jats:italic> functional LDLr activity studies to optimize the genetic diagnosis of FH avoiding the report of non-pathogenic variants and possible misdiagnose in relatives if cascade screening is carried out.<\/jats:p>","DOI":"10.1038\/s41598-018-34715-x","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T14:27:54Z","timestamp":1541428074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["p.(Asp47Asn) and p.(Thr62Met): non deleterious LDL receptor missense variants functionally characterized in vitro"],"prefix":"10.1038","volume":"8","author":[{"given":"A.","family":"Benito-Vicente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. B.","family":"Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jebari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Galicia-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Larrea-Sebal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ostolaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"34715_CR1","unstructured":"Goldstein, J. L., Hobbs, H. H. & Brown, M. S. Familial hypercholesterolemia. In: Scriver CR, AB, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. New York, N. Y.: McGraw-Hill (2001)."},{"key":"34715_CR2","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard, B. G. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34, 3478\u20133490a, https:\/\/doi.org\/10.1093\/eurheartj\/eht273 (2013).","journal-title":"Eur Heart J"},{"key":"34715_CR3","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"AV Khera","year":"2016","unstructured":"Khera, A. V. et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol 67, 2578\u20132589, https:\/\/doi.org\/10.1016\/j.jacc.2016.03.520 (2016).","journal-title":"J Am Coll Cardiol"},{"key":"34715_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.atherosclerosis.2011.02.006","volume":"216","author":"KR Chiou","year":"2011","unstructured":"Chiou, K. R., Charng, M. J. & Chang, H. M. Array-based resequencing for mutations causing familial hypercholesterolemia. Atherosclerosis 216, 383\u2013389, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.02.006 (2011).","journal-title":"Atherosclerosis"},{"key":"34715_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/joim.12263","volume":"276","author":"C Maglio","year":"2014","unstructured":"Maglio, C. et al. Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing. J Intern Med 276, 396\u2013403, https:\/\/doi.org\/10.1111\/joim.12263 (2014).","journal-title":"J Intern Med"},{"key":"34715_CR6","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/gim.2013.55","volume":"15","author":"J Vandrovcova","year":"2013","unstructured":"Vandrovcova, J. et al. The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. Genet Med 15, 948\u2013957, https:\/\/doi.org\/10.1038\/gim.2013.55 (2013).","journal-title":"Genet Med"},{"key":"34715_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12929-016-0256-1","volume":"23","author":"R Henderson","year":"2016","unstructured":"Henderson, R., O\u2019Kane, M., McGilligan, V. & Watterson, S. The genetics and screening of familial hypercholesterolaemia. J Biomed Sci 23, 39, https:\/\/doi.org\/10.1186\/s12929-016-0256-1 (2016).","journal-title":"J Biomed Sci"},{"key":"34715_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17, 405\u2013424, https:\/\/doi.org\/10.1038\/gim.2015.30 (2015).","journal-title":"Genet Med"},{"key":"34715_CR9","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/gim.2015.14","volume":"17","author":"A Benito-Vicente","year":"2015","unstructured":"Benito-Vicente, A. et al. The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia. Genet Med 17, 980\u2013988, https:\/\/doi.org\/10.1038\/gim.2015.14 (2015).","journal-title":"Genet Med"},{"key":"34715_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/humu.20201","volume":"26","author":"IF Fokkema","year":"2005","unstructured":"Fokkema, I. F., den Dunnen, J. T. & Taschner, P. E. LOVD: easy creation of a locus-specific sequence variation database using an \u201cLSDB-in-a-box\u201d approach. Hum Mutat 26, 63\u201368, https:\/\/doi.org\/10.1002\/humu.20201 (2005).","journal-title":"Hum Mutat"},{"key":"34715_CR11","doi-asserted-by":"publisher","first-page":"e112677","DOI":"10.1371\/journal.pone.0112677","volume":"9","author":"A Etxebarria","year":"2014","unstructured":"Etxebarria, A. et al. Advantages and versatility of fluorescence-based methodology to characterize the functionality of LDLR and class mutation assignment. PLoS One 9, e112677, https:\/\/doi.org\/10.1371\/journal.pone.0112677 (2014).","journal-title":"PLoS One"},{"key":"34715_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/humu.22721","volume":"36","author":"A Etxebarria","year":"2015","unstructured":"Etxebarria, A. et al. Functional characterization and classification of frequent low-density lipoprotein receptor variants. Hum Mutat 36, 129\u2013141, https:\/\/doi.org\/10.1002\/humu.22721 (2015).","journal-title":"Hum Mutat"},{"key":"34715_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/humu.21630","volume":"33","author":"A Etxebarria","year":"2012","unstructured":"Etxebarria, A. et al. Functional characterization of splicing and ligand-binding domain variants in the LDL receptor. Hum Mutat 33, 232\u2013243, https:\/\/doi.org\/10.1002\/humu.21630 (2012).","journal-title":"Hum Mutat"},{"key":"34715_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2011.12.021","volume":"221","author":"L Palacios","year":"2012","unstructured":"Palacios, L. et al. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis 221, 137\u2013142, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.12.021 (2012).","journal-title":"Atherosclerosis"},{"key":"34715_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1055\/s-0037-1613809","volume":"83","author":"R Dardik","year":"2000","unstructured":"Dardik, R. et al. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost 83, 338\u2013344 (2000).","journal-title":"Thromb Haemost"},{"key":"34715_CR16","doi-asserted-by":"crossref","first-page":"13282","DOI":"10.1016\/S0021-9258(18)37702-0","volume":"263","author":"V Esser","year":"1988","unstructured":"Esser, V., Limbird, L. E., Brown, M. S., Goldstein, J. L. & Russell, D. W. Mutational analysis of the ligand binding domain of the low density lipoprotein receptor. J Biol Chem 263, 13282\u201313290 (1988).","journal-title":"J Biol Chem"},{"key":"34715_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/humu.9021","volume":"19","author":"CF Bunn","year":"2002","unstructured":"Bunn, C. F., Lintott, C. J., Scott, R. S. & George, P. M. Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. Hum Mutat 19, 311, https:\/\/doi.org\/10.1002\/humu.9021 (2002).","journal-title":"Hum Mutat"},{"key":"34715_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/sj.ejhg.5200633","volume":"9","author":"KE Heath","year":"2001","unstructured":"Heath, K. E., Humphries, S. E., Middleton-Price, H. & Boxer, M. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur J Hum Genet 9, 244\u2013252, https:\/\/doi.org\/10.1038\/sj.ejhg.5200633 (2001).","journal-title":"Eur J Hum Genet"},{"key":"34715_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.atherosclerosis.2008.07.005","volume":"203","author":"Y Miyake","year":"2009","unstructured":"Miyake, Y. et al. Update of Japanese common LDLR gene mutations and their phenotypes: Mild type mutation L547V might predominate in the Japanese population. Atherosclerosis 203, 153\u2013160, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.07.005 (2009).","journal-title":"Atherosclerosis"},{"key":"34715_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.atherosclerosis.2013.01.007","volume":"227","author":"S Bertolini","year":"2013","unstructured":"Bertolini, S. et al. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis 227, 342\u2013348, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.01.007 (2013).","journal-title":"Atherosclerosis"},{"key":"34715_CR21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/humu.20256","volume":"26","author":"SW Fouchier","year":"2005","unstructured":"Fouchier, S. W., Kastelein, J. J. & Defesche, J. C. Update of the molecular basis of familial hypercholesterolemia in The Netherlands. Hum Mutat 26, 550\u2013556, https:\/\/doi.org\/10.1002\/humu.20256 (2005).","journal-title":"Hum Mutat"},{"issue":"2","key":"34715_CR22","doi-asserted-by":"publisher","first-page":"199-204.e2","DOI":"10.1016\/j.jpeds.2009.02.022","volume":"155","author":"Ornella Guardamagna","year":"2009","unstructured":"Guardamagna, O. et al. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr 155, 199\u2013204 e192, https:\/\/doi.org\/10.1016\/j.jpeds.2009.02.022 (2009).","journal-title":"The Journal of Pediatrics"},{"key":"34715_CR23","doi-asserted-by":"publisher","first-page":"e1004855","DOI":"10.1371\/journal.pgen.1004855","volume":"11","author":"AS Thormaehlen","year":"2015","unstructured":"Thormaehlen, A. S. et al. Systematic cell-based phenotyping of missense alleles empowers rare variant association studies: a case for LDLR and myocardial infarction. PLoS Genet 11, e1004855, https:\/\/doi.org\/10.1371\/journal.pgen.1004855 (2015).","journal-title":"PLoS Genet"},{"key":"34715_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/41798","volume":"388","author":"D Fass","year":"1997","unstructured":"Fass, D., Blacklow, S., Kim, P. S. & Berger, J. M. Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module. Nature 388, 691\u2013693, https:\/\/doi.org\/10.1038\/41798 (1997).","journal-title":"Nature"},{"key":"34715_CR25","doi-asserted-by":"publisher","first-page":"13059","DOI":"10.1021\/bi00040a017","volume":"34","author":"S Bieri","year":"1995","unstructured":"Bieri, S., Djordjevic, J. T., Daly, N. L., Smith, R. & Kroon, P. A. Disulfide bridges of a cysteine-rich repeat of the LDL receptor ligand-binding domain. Biochemistry 34, 13059\u201313065 (1995).","journal-title":"Biochemistry"},{"key":"34715_CR26","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s10038-004-0198-4","volume":"49","author":"T Iwasaki","year":"2004","unstructured":"Iwasaki, T. et al. The important role for betaVLDLs binding at the fourth cysteine of first ligand-binding domain in the low-density lipoprotein receptor. J Hum Genet 49, 622\u2013628, https:\/\/doi.org\/10.1007\/s10038-004-0198-4 (2004).","journal-title":"J Hum Genet"},{"key":"34715_CR27","doi-asserted-by":"publisher","first-page":"10994","DOI":"10.1021\/bi980452c","volume":"37","author":"S Bieri","year":"1998","unstructured":"Bieri, S. et al. Folding, calcium binding, and structural characterization of a concatemer of the first and second ligand-binding modules of the low-density lipoprotein receptor. Biochemistry 37, 10994\u201311002, https:\/\/doi.org\/10.1021\/bi980452c (1998).","journal-title":"Biochemistry"},{"key":"34715_CR28","doi-asserted-by":"publisher","first-page":"6334","DOI":"10.1073\/pnas.92.14.6334","volume":"92","author":"NL Daly","year":"1995","unstructured":"Daly, N. L., Scanlon, M. J., Djordjevic, J. T., Kroon, P. A. & Smith, R. Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor. Proc Natl Acad Sci USA 92, 6334\u20136338 (1995).","journal-title":"Proc Natl Acad Sci USA"},{"key":"34715_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1432-1033.1996.0214u.x","volume":"239","author":"JT Djordjevic","year":"1996","unstructured":"Djordjevic, J. T., Bieri, S., Smith, R. & Kroon, P. A. A deletion in the first cysteine-rich repeat of the low-density-lipoprotein receptor leads to the formation of multiple misfolded isomers. Eur J Biochem 239, 214\u2013219 (1996).","journal-title":"Eur J Biochem"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34715-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34715-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34715-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T11:29:24Z","timestamp":1671622164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34715-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["34715"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-34715-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"23 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Progenika Biopharma SA, is an Spanish biotech company founded in 2000 with headquarters in Derio, Bizkaia (SPAIN). Progenika Biopharma SA did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\u2019 salaries to M.S. and L.P. A.B.-V., H.S., K.B.U., S. J., U.G.-G., A.L.-S., H.O. and C.M. declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16614"}}